A Double Blind, Placebo Controlled, Positive Controlled, Randomized, Crossover Study to Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2013
At a glance
- Drugs Cangrelor; Moxifloxacin
- Indications Acute coronary syndromes; Coronary artery disease; Thromboembolism
- Focus Adverse reactions
- Sponsors The Medicines Company
- 17 Jan 2012 Actual patient number is 67 according to ClinicalTrials.gov.
- 15 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jun 2011 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.